Description
Teva Just Got Hit By Trump—So Why Does Wall Street See 38% Upside?
President Donald Trump’s proposed 100% tariff on imported generic drugs delivered an immediate shock to Teva Pharmaceutical Industries, sending its shares down nearly 4% as investors considered the consequences for one of the world’s largest generic-medicine manufacturers. The concern is understandable: generic drugs operate on thin margins, and sharply higher import costs could be difficult to absorb without increasing prices or relocating production. Yet Wall Street’s response has been notably less pessimistic. Teva carries an average Buy rating and an average analyst price target of $41.75, representing approximately 38% upside from its July 22 closing price of $30.15. The gap between the political headline and the analyst outlook reflects a company undergoing a significant transformation.
